Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06761703 · ClinicalTrials.gov registry record
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
A clinical trial, sponsored by Amgen.
- Completed
- Registry status
- 200
- Enrollment target
NCT06761703 is a clinical trial that has completed, run by Amgen. The registered enrollment target is 200 participants.
The verdict
NCT06761703 has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research and at home self-blood testing. This study will engage an active community of people using anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss to examine the willingness of participants to engage in a digital study, provide consent, and complete various study-related tasks, including a self-collected capillary blood sample for assay testing and health related surveys.
Interventions
- DEVICE TAP® Micro Select Device (Touch Activated Phlebotomy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2025-01-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06761703
The ClinicalTrials.gov registry entry for NCT06761703 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAP® Micro Select Device (Touch Activated Phlebotomy) is the first listed.
NCT06761703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06761703 about?
NCT06761703 is a clinical study titled "A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss". This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research and at home self-blood testing. This study will engage an active commu...
What is the current status of trial NCT06761703?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2024-11-14. Estimated completion is 2025-01-06.
What interventions are being tested in trial NCT06761703?
The interventions under investigation include: TAP® Micro Select Device (Touch Activated Phlebotomy) (DEVICE).
Who is sponsoring clinical trial NCT06761703?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.